详情页 - 四川省肿瘤医院知识库

资源类型：

文章类型：

作者：

Arndt Vogel[1] * ; Stephen Lam Chan[2] ; Zhenggang Ren[3] ; Yuxian Bai[4] ; Shanzhi Gu[5] ; Xiaoyan Lin[6] ; Zhendong Chen[7] ; Weidong Jia[8] ; Yongdong Jin[9]

; Yabing Guo[10] ; Xiaohua Hu[11] ; Alexander Valerievich Sultanbaev[12] ; Monika Pazgan-Simon[13] ; Margaryta Pisetska[14] ; Tsz Keung Nip[15] ; Haisong Zhang[15] ; Jinghua Du[15] ; Ann-Lii Cheng[16] ; Ahmed Omar Kaseb[17] ; Shukui Qin[18] ;

机构： [1]Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany [2]Chinese University of Hong Kong, Hong Kong, China [3]Department of Hepatic Oncology, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China [4]Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China [5]Department of Interventional Radiology, Hunan Cancer Hospital, Changsha, China [6]Department of Oncology, Fujian Medical University Union Hospital, Fuzhou, China [7]Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China [8]Department of General Surgery, Anhui Provincial Hospital, Hefei, China [9]Department of Medical Oncology, Sichuan Cancer Hospital and Institute/The Affiliated Cancer Hospital School of Medicine, UESTC, Chengdu, China [10]Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Liver Cancer Center, Guangzhou, China [11]Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China [12]State Autonomous Budgetary Healthcare Institution, Republican Clinical Oncological Dispensary of the MoH of Republic Bashkortostan, Ufa, Russian Federation [13]Department of Infectious Disease and Hepatology, Wroclaw Medical University, and Centrum Badań Klinicznych P.Napora, Wroclaw, Poland [14]Department of Liver and Pancreas Gland Oncosurgery, Communal Non-profit Enterprise "Regional Center of Oncology", Kharkiv, Ukraine [15]Jiangsu Hengrui Pharmaceuticals, Co., Ltd, Shanghai, China [16]National Taiwan University Hospital, Taipei, Taiwan [17]Department of Gastrointestinal Medical Oncology, MD Anderson Cancer Center, Houston, TX [18]Cancer Center of Nanjing, Jinling Hospital, Nanjing, China

出处：

ISSN：

语种：

被引次数：

WOS：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [1]Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

推荐引用方式(GB/T 7714)：

APA：

MLA：

Camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Final overall survival analysis of the phase 3 CARES-310 study

文献详情